Comprehensive Clinical and Laboratory Follow-up of a Female Patient With Ebola Virus Disease: Sierra Leone Ebola Virus Persistence Study

William J. Liu, 1, 2 Foday R. Sesay, 1, 2 Antoine Coursier, 1, 2 Barbara Knust, 1, a William J. Liu, 1, a Foday R. Sesay, 1, a Antoine Coursier, 1, a Barbara Knust, 1, a

Received 9 February 2019; accepted 15 February 2019.

© The Author(s) 2019. Published by Oxford University Press on behalf of Infectious Diseases Society of America. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com

The clinical, virologic, and immunologic findings in a female Ebola virus disease patient are described. During the long-term follow-up, Ebola virus RNA was detectable in vaginal fluid beyond 36 days after symptom onset, with nearly an identical genome sequence as in acute phase blood. Ebola-specific T cells retained activation at 56 days after disease onset.

Keywords. clinical sequelae; Ebola virus; immune responses; virus genome; virus persistence.

CLINICAL SYMPTOMS IN ACUTE DISEASE

A 38-year-old female presented signs of Ebola virus disease (EVD) while under contact surveillance after caring for a close relative who died of Ebola virus (EBOV) infection [1]. EVD was confirmed at day 2 after the onset of symptoms by a real-time reverse transcriptase polymerase chain reaction (RT-PCR) test performed on blood.

At day 3, she was admitted to the Military Hospital 34 (MH34) Ebola Treatment Unit (ETU) in Freetown, Sierra Leone. On arrival, her body temperature was 38°C, she was conscious, she was able to walk unaided, and her oxygen pulse saturation was normal. All clinical signs are included in Table 1. Initial treatment is detailed in Box 1. On the same day, she consented to enroll in the Convalescent Plasma for Early Ebola Virus Disease in Sierra Leone study [2] and was transfused successfully with 450 mL of convalescent plasma. No abnormal signs were noted throughout the process.

The patient’s clinical symptoms gradually improved from day 10 (Table 1). Ebola-specific RNA targets were detected in the blood at day 3, and again at day 9 [3, 4] (Figure 1A, Table 2).

At day 14, the patient presented a single episode of fainting with spasmodic generalized body contractions of unknown origin, treated as a grand mal seizure with a single dose of diazepam. One hour later, she was agitated and restless, with a Glasgow Coma Score of 10. Her pupils were responsive to light. Abnormal vitals included tachycardia (152 beats per minute) and elevated systolic blood pressure (148/88 mmHg). Her blood sugar was normal (5 mmol/L). She regained consciousness 2 hours later and continued her improved clinical course.

At day 15, a peripheral blood specimen tested by RT-PCR for EBOV was undetectable (Figure 1A). A second specimen collected at day 17 was also EBOV RNA undetectable, and the participant was discharged from the ETU on day 18.

FOLLOW-UP AS A SURVIVOR

On day 18, she was enrolled in the Sierra Leone Ebola Virus Persistence Study at the MH34 study site [5, 6]. The study participant reported no history of malaria, diabetes, or tuberculosis in the previous 3 months, and a rapid HIV screening test was negative. A blood sample and a first set of body fluid specimens were collected, as per routine study procedures [6].

During her second visit to the study site at day 36, relatives reported disorientation to time, space, and with numbers. Additional complaints can be found in Table 1. She was referred to a psychiatrist for clinical evaluation, and findings included depersonalization (a feeling that her personality has changed) and increased recent nightmares. She was diagnosed with acute traumatic or stress reaction and insomnia, and she received diazepam. Ophthalmologic examination was normal, although she complained of eye pain and had hemorrhagic sclera. During this visit, a blood specimen and a second set of body fluid specimens were collected.

At day 49, the participant came back for a third visit, during which blood and a vaginal swab specimen were collected. She did not report any health problems.

When seen again at the MH34 survivor clinic at day 57, she had additional symptoms (Table 1). She was treated with antimalarials (empirical treatment with artemether and...
lumefantrine), antibiotics (azithromycin), antipyretic/pain killer (paracetamol), multivitamin and mineral supplement, and oral rehydration salt solution. This clinic visit corresponded to the fourth visit as part of enrollment in the Sierra Leone Ebola Virus Persistence Study, and venous blood and a menstrual blood swab specimen (her second menstruation after ETU discharge) were collected.

At day 73, she reported fever, persisting insomnia, and loss of appetite (Table 1). She was treated with an antibiotic (ciprofloxacin), antidepressant (amitriptyline), antipyretic/pain killer (paracetamol), and multivitamin supplement. During this clinic visit, which corresponded to her fifth visit in the study, venous blood, tears, and vaginal swab specimens were collected. During her next 2 rounds of follow-up at days 176 and 210 and at days 261 and 268, respectively, additional specimens were collected (Table 2). At her follow-up visit at day 176, she reported weight loss, abscess in the right axilla of 1 month's duration, and a 1-week history of fever and joint pain. Blood smear was positive for malaria. She was treated with antimalarials (artemether and lumefantrine), antibiotics (amoxicillin), antipyretic/pain killer (paracetamol), nonsteroidal anti-inflammatory drugs (ibuprofen), and mineral supplements. She did not complain of any new health problems at day 210. At day 261, the participant complained of loss of appetite and generalized body pain. She did not complain of any new health problems at her visit at day 268.

### VIROLOGIC AND IMMUNOLOGIC TESTING

Six vaginal swabs were collected and tested by RT-PCR [3] in the SLE-CHN Bio-safety Lab [7, 8]. EBOV RNA was detected in the first 2 specimens at days 18 and 36 after symptom onset,
respectively (Figure 1A, Table 2). The threshold cycle (Ct) values increased over time, indicating a decreasing amount of EBOV RNA detected. Subsequent vaginal swab specimens were RT-PCR negative. Virus culture of the specimens collected at days 18 and 36 after symptom onset did not yield viable virus.

A nearly complete viral sequence was generated using unbiased next-generation sequencing (Illumina MiSeq) from the vaginal swab acquired on day 18 (MF326641). A comparison of viral sequences acquired from the blood on day 2 (KX121194; 99.7% coverage) and vaginal swab on day 18 (99.9% coverage with an average depth of 255 reads) indicated nearly identical sequences. Sequence differences included (1) a single nucleotide insertion at position 3040 within the VP35 5' noncoding region in the blood reference sequence (KX121194) that was only observed in 2/1537 sequences from the outbreak and was not observed in the sequence from the index case (KX121193), which may represent a sequencing or assembly artifact; and 2) a silent mutation in the polymerase (T11755A) of the vaginal swab sequence that represents a unique mutation to this outbreak. The sequences from both specimens were very closely related to the index patient's sequence from an acute blood specimen (KX121193).

As per study protocols, the participant received counseling regarding sexual risk reduction recommendations, and condom demonstrations were performed when she received the RT-PCR test results from her body fluids. As it was the first time, the study counselor had to deliver a positive test result for vaginal fluid, and additional briefings and preparations ensured that the results were provided to the female participant with measured caution and appropriate counseling.

Immune responses were evaluated on 7 convalescent venous blood samples collected from days 4 to 73 covering both the acute and convalescent phases [9]. The serological responses

All other body fluids (menstrual blood, oral swab, rectal fluid, sweat, tears, and urine) collected from the participant at time points ranging from day 18 to day 268 after symptom onset tested RT-PCR negative (Table 2).
to EBOV of the patient presented an ascending trend for IgG after virus infection (Figure 1B). The IgM titer at day 18 was 1600 and decreased to undetectable at day 36. The EBOV-glycoprotein and nucleoprotein-specific T-cell responses (Table 2) were detected at day 36 and retained at a high level at day 57 (Figure 1B).

**DISCUSSION**

The female participant described in this report was enrolled in the study from the first day of symptom onset during the quarantine after caring for a close relative who died of EBOV infection [1] and was followed up for >200 days after discharge from the ETU, which provided a unique opportunity to assess clinical manifestations and virus persistence during the acute phase and early stages of convalescence.

From the limited evidence available, there is precedence for detection of EBOV RNA in vaginal fluid after recovery from EVD. During the 2014–2016 West African Ebola epidemic, vaginal swabs from 6 female EVD survivors being treated in the United States and Europe were tested [10], and 2 patients had RT-PCR-negative results at a median of 24 days after symptom onset after previously testing positive (compared with the 17.5 days for duration of viremia), and our findings are consistent with these reports. Other reports, however, have found no evidence for EBOV RNA persistence in vaginal fluid, including 44 vaginal swabs from 20 convalescent females collected at 12 to 57 days after symptom onset that were all negative for
viral antigen by enzyme-linked immunosorbent assay and virus isolation [11], and 21 convalescent females who tested negative by RT-PCR at 40 to 190 days after symptom onset [12].

These findings confirm that short-term EBOV RNA persistence is possible in female survivors and call for closer attention to possible sexual transmission of Ebola virus in the immediate convalescent period. There is not currently sufficient information to quantify the risk of EBOV transmission through sexual intercourse from women with virus RNA detected in vaginal fluid. During the 2014–2016 epidemic, there were not any known cases of EVD linked to sexual activity with a recently recovered female survivor, which suggests that this transmission pathway, although plausible, may be uncommon. In any case, the persistence of EBOV RNA in our case and others raises concern for transmission after exposure to vaginal secretions.

After the virus RNA was no longer detectable in the blood, different clinical sequelae could still be observed for the patient reported here, especially from the central nervous system, including depersonalization, nightmares, and insomnia, and the ocular system, including hyperemic sclera and eye pain. Similar clinical sequelae of EVD survivors have been previously described, in some cases persisting for many months or years [13, 14]. It is currently unknown what host or environmental factors, if any, contribute to EBOV persistence and sequelae, although it has been demonstrated that the virus can evade detection and linger in immune-privileged sites like the eyes, testes, and central nervous system, where it may continue to actively replicate for several months after resolution of viremia [14]. EBOV RNA has been demonstrated in vaginal fluid, saliva, sweat, stool, rectal swab, and urine for variable but more limited time periods postrecovery, which may reflect delayed clearance from the body rather than active replication and persistence [12, 15].

EBOV-specific glycoprotein and nucleoprotein T-cell responses were detected at days 36 and 57 in this patient, in concordance with previous reports [16, 17], which illuminated unconventional immune memory to EBOV. Six Sudan virus survivors had serum levels of glycoprotein-specific IgG 12 years after disease onset [17]. In 2014, 2 EVD survivors cared for in the United States had Ebola-specific T cells with activation markers 1 month postdischarge and memory CD8+ T cells up to 144 days after disease onset [18]. The EBOV-specific immune memory including IgG and T-cell responses of the female Ebola survivor in this study demonstrated continued expression for at least 2 months after disease onset. Evaluation of the immune response during and after EBOV infection is important to elucidate the relationship between activated immune responses and virus RNA persistence in the body fluids of survivors, which need further investigation.

As mentioned, this patient also received convalescent plasma on day 3 after disease onset. However, the IgG level we tested on day 4 was detected at a low level but increased to 1:400 on day 15 and was maintained at at least this level afterward. These data may indicate that the convalescent plasma intervention did not notably impact IgG response against EBOV nucleoprotein. Furthermore, whether immunotherapy has an effective impact on viral clearance, especially at the immune-privileged sites, needs further evidence-based investigation.

These findings provide a general profile for the clinical and laboratory features of EBOV disease in a female case from the time of acute disease into convalescence. The persistence of EBOV RNA within the vaginal fluids of the female survivor for a short period of time underscores the need to provide all EVD survivors with preventive, gender-sensitive behavioral counseling on safe sex and with a sufficient supply of condoms.

Acknowledgments

The authors would like to thank the Ebola Virus Persistence Study participants, especially the participant described here, and the Sierra Leone study staff at 34 Military Hospital and Lungi Government Hospital. The authors also wish to acknowledge the support provided by the Sierra Leone Ministry of Health, Ministry of Social Welfare, Gender, and Children’s Affairs. The authors finally would like to thank Delaram Akhavein, Nick Cairns, Neill Keppie, and Tim Brooks from the Public Health England Laboratory for their support in providing Ct values for the first blood sample tested.

Disclaimer. The views expressed in this article are those of the authors and do not necessarily represent the official positions of the Sierra Leone Ministry of Health and Sanitation, the World Health Organization, the United States Centers for Disease Control and Prevention, or the Chinese Center for Disease Control and Prevention.

Ethics approval. The research protocol was approved by institutional review boards or ethics committees of the Sierra Leone Ministry of Health and Sanitation, the World Health Organization, the United States Centers for Disease Control and Prevention, and the Chinese Center for Disease Control and Prevention. The participant gave written informed consent. The procedures in the study were in accordance with the ethical standards of the Helsinki Declaration of the World Medical Association.

Genome accession number in GenBank. The Ebola genome generated in the current study is available at GenBank under the accession number MF326641.

Sierra Leone Ebola Virus Persistence Study Group. Sierra Leone Ministry of Health and Sanitation: Gibrilla Fadlu Deen (principal investigator), James Bangura, Amara Jambai, Faustine James, Aliè Wirie, Francis Yamba. Sierra Leone Ministry of Defence: Foday Sahr, Halima Fornah, Richard Kamara, Thomas A. Massaquoi, Foday R. Sesay. Sierra Leone Ministry of Social Welfare, Gender, Children’s Affairs: Tina Davies.

World Health Organization: Nathalie Brouet (principal investigator), Pierre Formenty, Anna E. Thorson, Archchun Ariyarajah, Florence Baingana, Marylin Carino, Antoine Courier, Sara N. Durski, Ndema Habib, Philippe Gaillard, Margaret O. Lamunu, Sihem Landoulsi, Jaclyn E. Marrinan, Suzanna L.R. McDonald, Dhamari Naidoo, Carmen Valle. United States Centers for Disease Control and Prevention: Barbara Knust (principal investigator), Neetu Abad, Aneesah Akbar-Uqdah, Gail Bolan, Kyle Bernstein, Jeffrey Brock, Elizabeth Ervin, Rachel Kachur, John D. Klena, Jill Huppert, Brandy Maddox, Tasneem Malik, Elissa Meites, Oliver Morgan, Bridget Mugisa, Stuart T. Nichol, Lydia Poromon, Christine Ross, Ute Stroßher. Chinese Center for Disease Control and Prevention: Wenbo Xu (principal investigator), Mifang Liang, Hongtu Liu, William Jun Liu, Guizhen Wu, Yong Zhang. Joint United Nations Programme on HIV/AIDS: Patricia Ongpin.

Financial support. This work was supported by the World Health Organization, the United States Centers for Disease Control and Prevention, the Chinese Center for Disease Control and Prevention, the Paul G. Allen Family Foundation, and the Joint United Nations Programme on HIV/AIDS,
including the Major Special Projects for Infectious Disease Research of China (grant 2016ZX10004-222-003). The WHO acknowledges the financial contribution of the WHO Ebola Response Program, the Paul G. Allen Family Foundation, and the United Nations Development Program (UNDP)—United Nations Population Fund (UNFPA)—UNICEF—WHO—World Bank Special Program of Research, Development and Research Training in Human Reproduction (HRP), a cosponsored program executed by the WHO in support of the Sierra Leone Ebola Virus Persistence Study.

**Potential conflicts of interest.** The authors have declared that no conflict of interest exists. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.

**References**

1. Alpren C, Sloan M, Boegler KA, et al; Interagency Investigation Team. Notes from the field: Ebola virus disease cluster - Northern Sierra Leone, January 2016. MMWR Morb Mortal Wkly Rep 2016; 65:681–2.
2. Winters V, Semple C. Convalescent plasma for early Ebola virus disease in Sierra Leone. ISRCTN Registry 2015; ISRCTN13990511.
3. Wang Q, Zhang Y, Wang HY, et al. Detection and analysis of Ebola virus in Sierra Leone-China friendship biosafety laboratory from March 11 to April 20, 2015. Biomed Environ Sci 2016; 29:443–7.
4. Naval Medical Research Center for the US Department of Defense. JVAP-MCS. 2013.
5. Deen GF, Broutet N, Marrinan JE, et al; Sierra Leone Ebola Virus Persistence Study Group. Implementation of a study to examine the persistence of Ebola virus in the body fluids of Ebola virus disease survivors in Sierra Leone: methodology and lessons learned. PLoS Negl Trop Dis 2017; 11:e0005723.
6. Han M, Gu J, Gao GE, Liu WJ. China in action: national strategies to combat against emerging infectious diseases. Sci China Life Sci 2017; 60:1383–5.
7. Liu WJ. On the ground in Western Africa: from the outbreak to the elapse of Ebola. Protein Cell 2016; 7:621–3.
8. Liu Y, Sun Y, Wu W, et al. serological investigation of laboratory-confirmed and suspected ebola virus disease patients during the late phase of the Ebola outbreak in Sierra Leone. Virol Sin 2018; 33:323–34.
9. Rodriguez LL, De Roo A, Guimard Y, et al. Persistence and genetic stability of Ebola virus during the outbreak in Kikwit, Democratic Republic of the Congo, 1995. J Infect Dis 1999; 179(Suppl 1):S170–6.
10. Green E, Hunt L, Ross JCG, et al. Viraemia and Ebola virus secretion in survivors of Ebola virus disease in Sierra Leone: a cross-sectional cohort study. Lancet Infect Dis 2016; 16:1052–6.
11. Mattia JG, Vandy MJ, Chang JC, et al. Early clinical sequelae of Ebola virus disease in Sierra Leone: a cross-sectional study. Lancet Infect Dis 2016; 16:331–8.
12. Varkey JB, Shantha JG, Crozier I, et al. Persistence of ebola virus in ocular fluid during convalescence. N Engl J Med 2015; 372:2423–7.
13. Kreuels B, Wichmann D, Emmerich P, et al. A case of severe Ebola virus infection complicated by gram-negative septicemia. N Engl J Med 2014; 371:2394–401.
14. McElroy AK, Akondy RS, Davis CW, et al. Human Ebola virus infection results in substantial immune activation. Proc Natl Acad Sci U S A 2015; 112:4719–24.
15. Sobarzo A, Ochayon DE, Lutwama JJ, et al. Persistent immune responses after Ebola virus infection. N Engl J Med 2013; 369:492–3.
16. McElroy AK, Akondy RS, Davis CW, et al. Human Ebola virus infection results in substantial immune activation. Proc Natl Acad Sci U S A 2015; 112:4719–24.
17. Wang Q, Zhou WM, Zhang Y, et al. Good laboratory practices guarantee biosafety of filoviruses, arenaviruses, and New World hantaviruses. Am J Trop Med Hyg 2010; 82:954–60.
18. Liu J, Zhang S, Tan S, et al. Revival of the identification of cytotoxic T-lymphocyte epitopes for immunological diagnosis, therapy and vaccine development. Exp Biol Med (Maywood) 2011; 236:253–67.